BriaCell Therapeutics Corp. Files 8-K
Ticker: BCTXZ · Form: 8-K · Filed: Sep 12, 2024 · CIK: 1610820
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-event
Related Tickers: BCTX
TL;DR
BriaCell filed an 8-K on 9/11/24 detailing material agreements and equity sales.
AI Summary
BriaCell Therapeutics Corp. announced on September 11, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events, including financial statements and exhibits. This filing follows a name change from Ansell Capital Corp. on June 13, 2014.
Why It Matters
This 8-K filing indicates significant corporate activity, including definitive agreements and equity sales, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — Filings related to material definitive agreements and unregistered equity sales can introduce financial and operational risks for a company.
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant
- Ansell Capital Corp. (company) — Former company name
- September 11, 2024 (date) — Date of earliest event reported
- June 13, 2014 (date) — Date of name change
FAQ
What type of material definitive agreement did BriaCell Therapeutics Corp. enter into?
The filing indicates a material definitive agreement was entered into on September 11, 2024, but the specific details of the agreement are not provided in this summary.
What is the significance of the 'Unregistered Sales of Equity Securities' item?
This item suggests that BriaCell Therapeutics Corp. has issued equity securities that were not registered with the SEC, which can have implications for dilution and investor rights.
When did BriaCell Therapeutics Corp. change its name?
The company changed its name from Ansell Capital Corp. on June 13, 2014.
What is the primary business of BriaCell Therapeutics Corp. according to the filing?
The filing lists the Standard Industrial Classification as 'PHARMACEUTICAL PREPARATIONS [2834]', indicating its primary business is in the pharmaceutical sector.
What is the filing date and the earliest event date reported?
The filing was made on September 12, 2024, and the earliest event reported is dated September 11, 2024.
Filing Stats: 1,067 words · 4 min read · ~4 pages · Grade level 10.9 · Accepted 2024-09-12 16:25:28
Key Financial Figures
- $0.69 — , no par value, at an offering price of $0.69 per common share. The Offering closed
- $8,504,250 — The Company received gross proceeds of $8,504,250 in connection with the Offering, before
- $0.8625 — 11, 2025, and have an exercise price of $0.8625 per common share. The Placement Agent W
Filing Documents
- form8-k.htm (8-K) — 55KB
- ex4-1.htm (EX-4.1) — 159KB
- ex5-1.htm (EX-5.1) — 17KB
- ex10-1.htm (EX-10.1) — 657KB
- ex99-1.htm (EX-99.1) — 18KB
- ex99-2.htm (EX-99.2) — 14KB
- ex5-1_001.jpg (GRAPHIC) — 11KB
- ex5-1_002.jpg (GRAPHIC) — 12KB
- ex5-1_003.jpg (GRAPHIC) — 9KB
- ex99-1_001.jpg (GRAPHIC) — 17KB
- 0001493152-24-036055.txt ( ) — 1393KB
- bctx-20240911.xsd (EX-101.SCH) — 4KB
- bctx-20240911_def.xml (EX-101.DEF) — 29KB
- bctx-20240911_lab.xml (EX-101.LAB) — 36KB
- bctx-20240911_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRIACELL THERAPEUTICS CORP. /s/ William V. Williams September 12, 2024 William V. Williams President and Chief Executive Officer